miRecule
Gaithersburg, US · Founded 2018 · Delaware corporation · 3 known investors
miRecule is a biotechnology company developing therapeutics, with programs focused on oncology. It applies RNA-based drug development approaches within the biotech industry.
Founders & leadership
AS
Anthony SalehExecutive Officer
AD
Anthony D. SalehCEO
DL
Dave LemusCOO/CFO
Investors · 3
Competitors · 10
by search overlapDiabetes Prevention Program9 shared keywords
ResearchGate9 shared keywords
Stanford blockchain7 shared keywords
Million Dollar Mile6 shared keywords
Cornell6 shared keywordsCornell University is a university in New York conducting research and education across fields including health, climate, agriculture, and technology.
Usnews5 shared keywords
Doximity5 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Iecure5 shared keywords
Emolecules5 shared keywords
George Washington University5 shared keywords
Companies competing with miRecule for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$1.5MraisedNov 2019 · 3 investors · BiotechnologyRule 506(b)
▶$1.5MraisedNov 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony SalehExecutive Officer
- Offering amount
- $2.3M
- Amount sold
- $1.5M
- Minimum investment
- $100K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $739.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $305K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $410.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.